In a 5-year EHR-based cohort, PsO patients initiating IL-17i had significantly lower incidence of PsA/IA vs IL-23i, IL-12/23i, or TNFi. IL-17i reduced time with PsA/IA by 45% vs IL-23i, 61% vs IL-12/23i, and 74% vs TNFi. Further research need investigate if IL-17i may delay https://t.co/0PTbXZpLbu

#ACR25 Abstr#2695 Inguinal lymph node biopsies pre- and post-OBI, RTX, BLIN & CD19 CAR-T showed complete tissue depletion with CAR-T. B-cells reduced but often incomplete with protein-based depleters; OBI being the best. Still don’t agree with “immune reset” @RheumNow #ACRBest https://t.co/Sq7m9sXlLP

#2660 In >8000 women, serum urate rose sharply during the menopausal transition, then plateaued after menopause. Hyperuricemia reached 4-5% post-menopause, up to 18% in obesity or low eGFR. Healthy body weight & kidney function pre-menopause may decrease HU later @RheumNow #ACR25 https://t.co/v6ai3lgAd2

kids w 👇 Undifferentiated #systemic #autoinflammatory #disease Rx #IL1i N=33 =boys &girls 3.5 yrs Sx Abst#2151 #ACR25 @ACRheum @RheumNow There are many periodic fever syndromes 🤔some mutations are not yet discovered Access to &use of Anakinra canukinumab Rilonacept https://t.co/IyTx0nFxKC

#ACR25 Please find my video summary on the Phase 3 RCTs results of Ianalumab in moderate to severe disease activity in #Sjogren Disease presented during Late Breaking Abstract session Abstr#LB24 #SjD @RheumNow https://t.co/ngCAglwAO0 https://t.co/PaUYsxhBKS

Abstract 2697: Compared to MMF, tacrolimus showed - similar SRR by week 96 (58.5% vs. 69.2%, OR 0.62; 95% CI 0.29-1.29) - similar time to renal AE/deaths (HR 0.70; 95% CI 0.37-1.35) - serious AEs less frequent (12.3% vs. 30.8%) @RheumNow #ACR25 https://t.co/o3LtgOp7St

In PsA patients, GLP-1 RA therapy led to significant weight loss and improvements in CRP, pain, lipids, and blood pressure. PsA outcomes improved proportionally with weight loss. Regression analyses revealed that each 1% reduction in body weight was associated with significant https://t.co/Pph1PjfOve

Abstract 2696: Phase 1/2 study of rapidly engineered CD19 CAR T showed: - rapid depletion of CD19 B cells w/ recovery by Day 90 - Days 180 and 360: returning B cells largely naive (CD27-IgD+) - Interferon expression ↓ after CAR T treatment @RheumNow #ACR25 https://t.co/FzdFbqWwtE

#ACR25 Abstr#2697 H2H RCT of Tacrolimus + GC vs MMF + GC in #lupus Nephritis in Asia for Induction-Maintenance showed similar efficacy. Different side effects: AKI more in TAC, low WCC & infections in MMF. Informative for services with no access to biologics/Voclosporin @RheumNow https://t.co/V4uWhuqjjW